Vaccine Advisory Committee Reconsiders Hepatitis B Shot for Newborns
A federal vaccine advisory committee made a significant change on Friday, deciding to no longer recommend that all U.S. newborns receive the hepatitis B vaccine immediately after birth.
This decision drew sharp criticism from various medical professionals and public health leaders, particularly since the current committee was appointed by U.S. Health Secretary Robert F. Kennedy Jr., known for his anti-vaccine stance prior to taking on this role.
Dr. William Schaffner, a seasoned vaccine expert at Vanderbilt University, remarked, “This is the group that can’t shoot straight.”
Many medical societies and state health departments plan to maintain their recommendations for the birth dose. The trade group AHIP, formerly America’s Health Insurance Plans, noted that its members would still cover the hepatitis B vaccine at birth, although some might review their policies.
Historically, the government has advised vaccinating all babies against hepatitis B right after birth, viewing the shots as a successful public health measure that has prevented numerous infections.
Now, Kennedy’s Advisory Committee on Immunization Practices suggests the birth dose only for infants whose mothers test positive for the virus or haven’t been tested. For other children, the choice will be left to parents and their healthcare providers. The committee voted 8-3 in favor of starting the vaccination series at two months for families who choose to delay.
Jim O’Neill, the acting head of the CDC, will ultimately decide whether to accept this new recommendation.
A Shift in Health Strategy
This change marks a significant departure from a health strategy that has been in place for over three decades. Committee member Vicky Pebsworth mentioned “pressure from stakeholder groups” when explaining the committee’s decision to reexamine the recommendation.
Members argued that the risk of infection is low for most babies and that prior research supporting the vaccine’s safety in newborns was insufficient. They expressed concerns that healthcare providers often fail to discuss the risks and benefits of administering the vaccine at birth.
Despite wanting to hear from public health professionals, the committee chose not to heed repeated calls to maintain the original recommendations.
The committee advises the CDC on vaccine usage, and while directors typically adopt its suggestions, the agency currently lacks a permanent director, leaving O’Neill to make the call.
This year, Kennedy dismissed the previous 17-member panel, replacing it with members who include notable anti-vaccine advocates.
Understanding Hepatitis B and Birth Dose Delays
Hepatitis B is a serious liver infection that can last for less than six months for some, but can develop into long-lasting issues for infants and children, potentially leading to liver failure and cancer.
It’s mostly spread through sexual contact or shared needles among adults, but can also be transmitted from an infected mother to her baby.
In 1991, the committee had recommended administering the first hepatitis B vaccine at birth. Experts emphasized that prompt immunization is crucial to prevent infection. And indeed, instances in children have significantly decreased since then.
However, some committee members felt uneasy about vaccinating all newborns, citing that past safety studies were limited and that larger studies might reveal unforeseen issues. Others pointed out that they hadn’t encountered documented harm from the birth doses and believed the concerns were speculative.
Some members questioned the justification for delaying the first dose for two months and highlighted that there was no data to support this cutoff.
Dr. Joseph Hibbeln found this proposal “unconscionable,” expressing his ongoing opposition during a heated discussion. The committee chair mentioned two months as an age when infants have progressed beyond the neonatal stage, but Hibbeln contested that this cutoff wasn’t backed by evidence.
Dr. Cody Meissner raised concerns about another proposal, which was accepted 6-4, suggesting that parents could consult pediatricians about blood tests to check if the hepatitis B shots produced protective antibodies. This kind of testing isn’t common pediatric practice, and some argued it would be an unreliable way to assess the adequacy of fewer doses.
A CDC expert noted that results can vary widely among children, further complicating the assessment of vaccination effectiveness. Some members criticized the proposal’s wording as misleading.
Potential Public Health Implications
Health experts expressed concern that Kennedy’s committee may be shifting focus toward individual vaccination risks rather than viewing vaccinations as a public health measure aimed at curbing the spread of preventable diseases.
The second proposal was described by Dr. Robert Malone as emblematic of this troubling shift.
Critics of the meeting pointed out a significant change in how discussions are conducted; CDC scientists no longer present data on vaccine safety and effectiveness. Instead, individuals with anti-vaccine backgrounds have been prioritized during discussions.
Elizabeth Jacobs, from an advocacy group opposing certain health policies, stated that the committee has lost its scientific integrity, describing the meeting as an “epidemiological crime scene.”
Republican Senator Bill Cassidy, a liver specialist, deemed the committee’s new direction a mistake, asserting it would make the population “sicker.”
The committee heard presentations, including one from a lawyer known for collaborating with Kennedy on vaccine litigation, who claimed the committee shouldn’t make any vaccine recommendations at all.
In a rebuttal, Meissner criticized this viewpoint as a distortion of facts and commented on the questionable judgment to invite such speakers.
The organizers explained they had also invited vaccine advocates to participate, but some declined, including a noted vaccine researcher who felt the committee’s purpose had drifted away from evidence-based medicine.
